



30. Bericht der ÖGNÄ-HIV-Kohorte

1. Halbjahr 2023


1. DIE ZAHLEN

Patienten Geschlecht und Alter	2075
Männlich	1865
Weiblich	210
0-20	4
20-30	111
30-40	500
40-50	606
50-60	540
60-70	248
70-80	57
80-100	9

ART	2074	
KEINE ART	1	
Substanzgruppe	Medikament	Anzahl
NRTI	Abacav./Lamivud.	40
	Descovy	75
NNRTI NRTI/NNRTI	Viramune	63
	Edurant	128
	Emtr./Tenof.	67
	Emtr./Tenof./Efav.-STR	54
	Eviplera – STR	38
	Odefsey - STR	124
	Delstrigo - STR	151
	PI	Prezista
INI, NRTI/INI	Isentress	39
	Tivicay	110
	Triumeq - STR	64
	Genvoya - STR	72
	Biktarvy - STR	437
	Dovato	742
	Vocabria/Rekambis	119


Medikamente unter 10 Patienten: Lamivudine 2, Combivir 4, Trizivir 2, Emtriva 2, Truvada 1, Kivexa 3, Eпивir 8, Stocrin: 1, Efavirenz: 8, Pifeltro: 12, Intellence: 4, Stribild 8, Reyataz 2

2. HIV in Österreich




Daten von AKH-Wien, Penzing-Wien, Favoriten-Wien, AKH-Linz, UNI-Innsbruck, LKH-Graz-West, LKH-Klagenfurt, LKH-Salzburg, KH-Feldkirch sind von 03/2023

3. HIV in Wien





Daten von AKH-Wien, Penzing-Wien, Favoriten-Wien sind von 03/23

4. Infektionswege




5. ALTER UND GESCHLECHT




6. RESISTENZEN

Patient	RTI	PI	INSTI
1	V179D		
2	S68N E138EG		

7. STI-COINFEKTIONEN





8. ART UND KEINE ART





ART	2074
KEINE ART	1

9. ART NACH SUBSTANZGRUPPEN





10.ART – NRTI






- Kivexa
- Abacavir/Lamivudine
- Triumeq
- Truvada
- Emtricitabine/Tenofovir
- Descovy
- Atripla
- Eviplera
- Odefsey
- Stribild
- Genvoya
- Delstrigo
- Biktarvy
- Dovato

12.ART – PI




13.ART – INSTI




14.ART – NEUEINSTELLUNGEN

	Medikamente	CD4	VL
1	Biktarvy	670	47
2	Biktarvy	424	4000
3	Dovato	623	4200
4	Biktarvy ^G	191	550000
5	Triumeq ^B	560	<30
6	Biktarvy	1069	
7	Biktarvy	564	
8	Biktarvy	710	
9	Dovato	679	
10	Biktarvy ^F	591	
11	Bictarvy	732	911
12	Bictarvy	1079	4200
13	Bictarvy	743	36000
14	Bictarvy	812	245
15	Bictarvy	545	2000
16	Markus		




14A. ART – UMSTELLUNGEN

Substanzen nach Umstellung




ART neu	ART alt
Vocabria/Rekombys 119x	Dovato 51x
	Biktarvy 24x
	Odefsey 13x
	Delstrigo 12x
	Genvoya 4x
	Stribild 1x
	Truvada/Viramune 1x
	Descovy/Prezista 1x
	Atripla 1x
	ABC/3TC/Viramune 1x
	Celsentry/Prezista/N 1x
	Triumeq 4x
	Emtri/Teno/Efa 2x
	Kivexa/Isentress 1x
	Kivexa/Tivicay 1x
	Atripla 1x
Delstrigo 7x	Genvoya, Biktarvy, Atripla, Stribild, Vocabria/Rekombis, Dovato, ABC/3TC/EFA
Dovato 6x	Stribild, Triumeq, Odefsey Genvoya, Kivexa/Viramune, Biktarvy
Biktarvy ^{G+B} 7x	Delstrigo 2x, Genvoya, Descovy/Tivicay, Descovy/Prezista/N Emtri/Teno/Efavirenz, ABNC/3TC/EFA


14B. ALTER DER VOCABRIA/REKAMBIS-PATIENTEN




14C. ART – KEINE ART – ZEITLICH




15.ART – SINGLE TABLET REGIME



16.DUALTHERAPIEN





17.PREP

